Journey Medical Corporation
NCM: DERMLive Quote
📈 ZcoreAI Score
Our AI model analyzes Journey Medical Corporation's price action across multiple timeframes using regression channels and statistical scoring.
Get DERM Z-Score →About Journey Medical Corporation
Healthcare
Drug Manufacturers - Specialty & Generic
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
📊 Fundamental Analysis
Journey Medical Corporation demonstrates a profit margin of -18.5%, which is below the sector average, suggesting competitive pressure.
The company recently reported 18.1% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -44.0%, which indicates that capital utilization is currently under pressure.
At a current price of $5.17, DERM currently trades near the bottom of its 52-week range (16%), indicating potential value or weakness (Range: $4.31 - $9.55).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$171.94M
Trailing P/E
--
Forward P/E
-86.17
Beta (5Y)
1.04
52W High
$9.55
52W Low
$4.31
Avg Volume
205K
Day High
Day Low